Side-by-side · Research reference
GHRP-6vsTestagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1HUMAN-REVIEWED10/36 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
GHRP-6
Hexapeptide GHRP · Strong appetite stimulant
SQ · Multiple sites · 1–3×/day
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
01Mechanism of Action
Parameter
GHRP-6
Testagen
Primary target
Ghrelin receptor (GHS-R1a)Bowers 1990
Testicular tissue; proposed nuclear DNA interaction
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
—
Unknown — no HPG axis data
Origin
Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Antibody development
—
—
02Dosage Protocols
Parameter
GHRP-6
Testagen
Frequency
1–3× per day
Once daily or alternate days
Lower / starter dose
50 mcg per dose
—
Evidence basis
Phase 1 + clinical practiceBowers 1990
Animal mechanistic / in vitro onlyFedoreyeva 2011
Duration
8–12 weeks on / 4 off
—
Reconstitution
Bacteriostatic water
Sterile water or bacteriostatic saline
Timing
Pre-meal preferred for appetite support
—
Typical protocol (anecdotal)
—
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Cycle length
—
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Route
—
Subcutaneous
04Side Effects & Safety
Parameter
GHRP-6
Testagen
Hunger
Pronounced — defining feature vs ipamorelin
—
Cortisol elevation
Mild
—
Prolactin elevation
Mild
—
Injection site reaction
Mild
—
Cancer risk
Contraindicated in active malignancy
—
Pregnancy / OB
Avoid
—
Injection site reactions
—
Erythema, mild irritation (potential)
Systemic effects
—
Unknown — no human safety data
Hormonal impact
—
No published data on testosterone, LH, FSH effects
Long-term safety
—
Unknown — no long-term studies
Absolute Contraindications
GHRP-6
- ·Active malignancy
- ·Pregnancy / breastfeeding
Testagen
- ·Active testicular malignancy
Relative Contraindications
GHRP-6
- ·Severe insulin resistance (appetite-driven caloric load)
Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
05Administration Protocol
Parameter
GHRP-6
Testagen
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Injection site
SQ — abdomen. Rotate sites.
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Timing
Pre-meal for appetite support; pre-sleep for GH alignment.
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Needle
29–31G, 4–8 mm insulin syringe.
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.